Unicycive Therapeutics, Inc., a biotechnology company headquartered in Los Altos, United States, has been making strides in the healthcare sector with its focus on developing innovative therapies. The company specializes in addressing hyperphosphatemia, a condition characterized by elevated phosphate levels in the blood, which is particularly prevalent among patients suffering from chronic kidney disease (CKD) and acute kidney injury (AKI).
As of April 30, 2026, Unicycive Therapeutics’ stock was trading at a close price of $7.67 on the Nasdaq exchange. This figure reflects a notable fluctuation over the past year, with the stock reaching a 52-week high of $11 on June 8, 2025, and a 52-week low of $3.71 on September 24, 2025. The company’s market capitalization stands at approximately $193.57 million, indicating its valuation within the biotechnology sector.
Despite its promising developments in therapeutic research, Unicycive Therapeutics has reported a negative price-to-earnings (P/E) ratio of -4.61. This metric suggests that the company is currently not generating profits, which is not uncommon for biotech firms heavily invested in research and development. The negative P/E ratio underscores the company’s focus on long-term growth and innovation rather than immediate financial returns.
Unicycive Therapeutics’ commitment to advancing treatments for hyperphosphatemia is driven by the significant need for effective management of phosphate levels in patients with CKD and AKI. Elevated phosphate levels can lead to severe complications, including cardiovascular disease, making the development of effective therapies crucial for improving patient outcomes.
The company’s strategic focus on these two novel therapies positions it as a key player in the biotechnology landscape, particularly within the niche of kidney-related health issues. As Unicycive Therapeutics continues to progress through its research and development phases, it remains to be seen how its innovative approaches will impact the market and patient care in the coming years.
